BAIT
CYP4F12
CYPIVF12, F22329_1, UNQ568/PRO1129
cytochrome P450, family 4, subfamily F, polypeptide 12
GO Process (15)
GO Function (4)
GO Component (4)
Gene Ontology Biological Process
- arachidonic acid metabolic process [ISS]
- drug metabolic process [ISS]
- epoxygenase P450 pathway [ISS]
- leukotriene B4 catabolic process [ISS]
- long-chain fatty acid metabolic process [ISS]
- negative regulation of blood coagulation [ISS]
- oxidation-reduction process [ISS]
- pressure natriuresis [ISS]
- renal water homeostasis [ISS]
- small molecule metabolic process [TAS]
- sodium ion homeostasis [ISS]
- very long-chain fatty acid metabolic process [ISS]
- vitamin E metabolic process [ISS]
- vitamin K biosynthetic process [ISS]
- xenobiotic metabolic process [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
RPS6KA4
MSK2, RSK-B
ribosomal protein S6 kinase, 90kDa, polypeptide 4
GO Process (14)
GO Function (5)
GO Component (3)
Gene Ontology Biological Process
- axon guidance [TAS]
- histone H3-S10 phosphorylation [IMP]
- histone H3-S28 phosphorylation [IMP]
- histone phosphorylation [TAS]
- interleukin-1-mediated signaling pathway [IMP]
- intracellular signal transduction [IDA]
- negative regulation of cytokine production [TAS]
- positive regulation of CREB transcription factor activity [TAS]
- positive regulation of NF-kappaB transcription factor activity [TAS]
- positive regulation of histone acetylation [IMP]
- positive regulation of histone phosphorylation [IMP]
- positive regulation of transcription from RNA polymerase II promoter [IMP]
- protein phosphorylation [IDA]
- regulation of transcription, DNA-templated [IDA]
Gene Ontology Molecular Function
Homo sapiens
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.
Identification of effective combination therapies is critical to address the emergence of drug-resistant cancers, but direct screening of all possible drug combinations is infeasible. Here we introduce a CRISPR-based double knockout (CDKO) system that improves the efficiency of combinatorial genetic screening using an effective strategy for cloning and sequencing paired single guide RNA (sgRNA) libraries and a robust statistical scoring ... [more]
Nat. Biotechnol. Mar. 20, 2017; 0(); [Pubmed: 28319085]
Quantitative Score
- -5.678 [Confidence Score]
Throughput
- High Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507)
Additional Notes
- CRISPR GI screen
- Cell Line:K562 (EFO:0002067)
- Experimental Setup:Timecourse
- GIST: A-phenotypic negative genetic interaction
- Library:Drug Target-CDKO CRISPRn library
- Significance Threshold: q-value<0.05
Curated By
- BioGRID